In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…
Using data from cohorts with detailed lifestyle data and lengthy follow-up, Hahn et al. demonstrated that healthy lifestyle behaviors are associated with a lower risk of developing rheumatoid arthritis (RA), concluding that a substantial proportion of RA may be preventable.
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.
New analyses of treat to target in gout may lead to revisions in some guidelines.
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
Since the beginning of the pandemic, the ACR’s Committee on Training and Workforce (COTW) has been interested in better understanding how fellowship recruitment is affected by virtual recruitment from the perspectives of both program directors and trainees. This past year, the COTW conducted a survey study to gain the perspective of program directors.1 The Rheumatology…
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…
All of us have a professional story to share. We have come from various backgrounds that make us different and allow us to link unique contributions from our professional journey. Some of us dedicate our careers to academics, many serve in private practice, and others have a combination of career experiences. Unfortunately, many of our…